Kytril (Granisetron)

Granisetron blocks serotonin (5‑HT3) receptors located in the chemoreceptor trigger zone of the brain and on vagal afferents in the gastrointestinal tract. By preventing serotonin from binding, it interrupts the emetic signaling cascade that normally triggers nausea and vomiting, thereby providing anti‑emetic protection during chemotherapy or postoperative periods.

The specific dose of Kytril is determined by the prescribing clinician based on the patient’s treatment regimen, type of chemotherapy, and individual risk factors. Dosage may vary for adult and pediatric patients, and the prescriber will select the appropriate tablet strength and timing to achieve optimal anti‑emetic control.

Safety data for granisetron in pregnancy and lactation are limited, and the drug is generally classified as category unknown. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the Kytril product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any temperature requirements) and necessary import documentation.

Compared with other 5‑HT3 antagonists such as ondansetron, granisetron has a longer half‑life and may be administered once daily, offering convenient dosing. It shares a similar efficacy profile for chemotherapy‑induced nausea, but individual patient response and tolerability can differ, so clinicians choose the agent that best fits the therapeutic context and safety considerations.

Kytril tablets should be stored at room temperature, below 25 °C, in their original blister pack or container to protect them from moisture and light. Keeping the medication in a dry environment helps maintain its stability and potency throughout its shelf life. Do not store in bathrooms or near heat sources.

Kytril is taken orally as a tablet, usually with a glass of water. The timing of administration is often 30 minutes before chemotherapy or surgery, as directed by the prescriber, to ensure adequate plasma levels at the onset of the emetogenic stimulus. Swallow the tablet whole; do not crush or chew unless instructed.

Although rare, serious adverse reactions can include severe allergic responses such as anaphylaxis, cardiac arrhythmias or QT‑interval prolongation, and profound constipation that may lead to bowel obstruction. Patients should be monitored for signs of hypersensitivity, cardiac symptoms, or gastrointestinal distress, and any severe event should prompt immediate medical attention.

Kytril is contraindicated in individuals with known hypersensitivity to granisetron or any component of the tablet formulation. Caution is also advised for patients with a history of prolonged QT interval, significant cardiac disease, or electrolyte abnormalities, as these conditions may increase the risk of serious cardiac events. Such patients should discuss alternative anti‑emetic options with their healthcare provider.